Patients with Fabry disease (FD) report impaired quality of life and excessive daytime sleepiness. Obstructive sleep apnea (OSA) is frequently reported among patients with FD; however, its prevalence and its influence on quality of life and daytime sleepiness in this population are unclear.
Patients with FD in a cohort from the University Hospital Zurich (n = 52) were one-to-two matched to healthy adult controls (n = 104) according to age, sex, and body mass index. Participants underwent structured interviews (including Short Form-36) and level-3 respiratory polygraphy. An apnea-hypopnea index of ≥ 5/h was defined as OSA and the severity of FD was quantified with the Mainz Severity Score Index (MSSI). Conditional logistic regression was used to compare the outcomes.
In patients with FD the mean MSSI was 13.3 ± 10.5 points and OSA prevalence was 19.2% vs. 9.0% in the matched control group (p = 0.09). The apnea-hypopnea index was significantly higher in patients with FD than in the control group (0.5/h [0.2–3.0] vs. 0.2/h [0.1–1.8], p = 0.026). OSA severity was associated with impaired quality of life in four dimensions for the whole study population. Furthermore, patients with FD did report significantly higher daytime sleepiness (Epworth Sleepiness Scale 7.6 points vs. 6.3 points; p = 0.01) than healthy controls.
Patients with mild FD do not have a higher OSA prevalence than matched control subjects. Differences in OSA severity did not reach clinical significance. Further studies are warranted to determine the impact of OSA in patients with moderate-to-severe FD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Data access, responsibility, and analysis
TG and DF had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Body mass index
Epworth Sleepiness Scale
Mainz Severity Score Index
Obstructive sleep apnea
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40
Desnick R, Ioannou Y, Eng C. (2001) α-galactosidase A Deficiency: Fabry disease. The metabolic and molecular bases of inherited disease. (eds Scriver CR, Beaudet AL, Sly WS, Valle D.) p3733-3774. In: McGraw-Hill, New York
Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338–346
Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf el Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R (2016) Treatment of Fabry’s disease with the pharmacologic chaperone Migalastat. N Engl J Med 375(6):545–555
Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M (2017) Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis 41(1):141–149
Duning T, Deppe M, Keller S, Schiffbauer H, Stypmann J, Böntert M, Schaefer R, Young P (2009) Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol 1(1):33–40
Talbot A, Hammerschlag G, Goldin J, Nicholls K (2017) Sleep disturbance, obstructive sleep apnoea and abnormal periodic leg movements: very common problems in Fabry disease. JIMD Rep 31:37–44
Franzen D, Gerard N, Bratton DJ, Wons A, Gaisl T, Sievi NA, Clarenbach CF, Kohler M, Krayenbühl PA (2015) Prevalence and risk factors of sleep disordered breathing in Fabry disease: a prospective cohort study. Medicine (Baltimore) 94(52):e2413
Bratton DJ, Gaisl T, Schlatzer C, Kohler M (2015) Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med 3(11):869–878
Kuhn E, Schwarz EI, Bratton DJ, Rossi VA, Kohler M (2017) Effects of CPAP and mandibular advancement devices on health-related quality of life in OSA: a systematic review and meta-analysis. Chest. 151(4):786–794
Lacasse Y, Godbout C, Series F (2002) Health-related quality of life in obstructive sleep apnoea. Eur Respir J 19(3):499–503
Lohle M, Hughes D, Milligan A, Richfield L, Reichmann H, Mehta A, Schapira AHV (2015) Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 84(14):1454–1464
Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J (2015) Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3(4):310–318
Bloch KE, Schoch OD, Zhang JN, Russi EW (1999) German version of the Epworth Sleepiness Scale. Respiration; international review of thoracic diseases 66(5):440–447
Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307
Iber C American Academy of Sleep Medicine, Chesson AL, Qaun SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications (1st edn). Westchester: American Academy of Sleep Med
Cho JH, Kim HJ (2017) Validation of ApneaLink Plus for the diagnosis of sleep apnea. Sleep & breathing = Schlaf & Atmung 21(3):799–807
Gaisl T, Giunta C, Bratton DJ, Sutherland K, Schlatzer C, Sievi N, Franzen D, Cistulli PA, Rohrbach M, Kohler M (2017) Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study. Thorax. 72(8):729–735
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM (2013) Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177(9):1006–1014
Suhani P, Samantha SK, Claire MN et al (2017) Minimum clinically important difference of the Epworth Sleepiness Scale. Eur Respir J 50(Issue suppl):61
El Shayeb M, Topfer LA, Stafinski T, Pawluk L, Menon D (2014) Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis. CMAJ. 186(1):E25–E51
Corral J, Sanchez-Quiroga MA, Carmona-Bernal C et al (2017) Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Noninferiority, randomized controlled trial. Am J Respir Crit Care Med 196(9):1181–1190
We thank the patients and relatives who gave so much for this study and often traveled long distances in order to participate in this study; without them, this study would not have been possible.
Conflict of interest
Albina Nowak received lecturing honoraria and research support from Sanofi Genzyme and Shire—outside the submitted work. Thomas Gaisl and Malcolm Kohler worked as consultants for Bayer AG—outside the submitted work. All other authors (Noriane A. Sievi, Nicolas Gerard, Christian F. Clarenbach, Daniel Franzen) declare that they have no conflict of interest.
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in this study.
All authors have seen and approved the final manuscript. This manuscript does not report on a clinical trial.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Institution where work was performed: University Hospital Zurich, Switzerland
About this article
Cite this article
Gaisl, T., Nowak, A., Sievi, N.A. et al. Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study. Sleep Breath 24, 95–101 (2020). https://doi.org/10.1007/s11325-019-01832-4
- Obstructive sleep apnea
- Fabry disease
- Quality of life